In a move that could transform mental health treatment in America, the Food and Drug Administration has awarded ultra-fast priority review vouchers to three psychedelic drug programmes, signalling that these once-taboo substances are closer than ever to becoming legitimate medicines.
What Just Happened
On April 24, 2026, the FDA announced priority review vouchers for:
- Two psilocybin programmes (the active ingredient in magic mushrooms) targeting treatment-resistant depression
- One methylone programme (related to MDMA) for post-traumatic stress disorder (PTSD)
Priority review vouchers mean regulators will try to shorten their review timeline from months to just weeks — a dramatic acceleration.
Why It Matters
An estimated 21 million adults in the US experience at least one major depressive episode each year, and roughly 6% of the population will experience PTSD at some point in their lives. For many, existing treatments simply don't work well enough.
Early clinical trials of psilocybin-assisted therapy have shown remarkable results: in some studies, a single dose combined with therapy produced significant improvement in depression symptoms that lasted months or even years. Methylone has shown similar promise for PTSD, helping patients process traumatic memories in ways traditional therapy alone often cannot.
A Shift in Thinking
FDA Commissioner Marty Makary framed the decision in terms of urgency: “We owe it to our nation's veterans and all Americans who are suffering from these conditions to evaluate these potential therapies with urgency.”
The move follows a presidential executive order directing federal agencies to speed psychedelic research and loosen restrictions. It reflects growing mainstream acceptance of these substances as legitimate medical tools — a dramatic shift from their blanket prohibition decades ago.
What Comes Next
The vouchers don't guarantee approval, but they clear a major bureaucratic hurdle. If the data holds up under accelerated review, the first FDA-approved psychedelic therapy could arrive within months — offering hope to millions who've struggled with conventional treatments.
Sources: Fortune, CNN, Associated Press, FDA press release (April 24, 2026)
